Printer Friendly

Voriconazole: salvage therapy.

Voriconazole was effective and well tolerated for refractory, uncommon, and new fungal infections in a recent study of patients at high risk for treatment failure.

The broad-spectrum triazole led to satisfactory global responses in 47% of 273 patients with fungal infections refractory to other antifungals, and in 68% of 28 patients with infections for which there is no approved treatment, reported Dr. John R. Perfect of Duke University, Durham, N.C., and his colleagues. Treatment was effective in 44% of patients with aspergillosis, 55% with candidiasis, 39% with cryptococcosis, 45% with fusariosis, 90% with penicilliosis, and 30% with scedosporiosis. Adverse effects occurred in 58% of patients; fewer than 10% discontinued or reduced treatment as a result (Clin. Infect. Dis. 36[9]: 1122-31,2003).

Although underlying conditions and previous treatments were shown to affect clinical outcomes, survival at 90 days in those on voriconazole was 66%. This is "encouraging evidence" of the drug's efficacy in a seriously ill population, particularly since about 75% of the study patients failed to respond to previous treatments, they said.
COPYRIGHT 2003 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Clinical Capsules
Author:Worcester, Sharon
Publication:Internal Medicine News
Article Type:Brief Article
Date:Aug 1, 2003
Previous Article:Flu: prevention and treatment.
Next Article:West Nile paralysis.

Related Articles
Antifungal Arsenal to expand in 2002. (More Immunocompromised Patients).
Treating invasive aspergillosis.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters